Neurotrophic factors in bipolar disorders patients with manic episode

Background/aim: Neurotrophins are one of the most important molecule groups affecting cerebral neuroplasticity. The amount of evidence about the role of changes in neuroplasticity in the pathophysiology of bipolar disease is growing. Materials and methods: We measured serum levels of brain-derived neurotrophic factor BDNF , nerve growth factor NGF , neurotrophin-3 NT-3 , glial cell-line derived neurotrophic factor GDNF , vascular endothelial growth factor VEGF , insulin-like growth factor-1 IGF-1 , fibroblast growth factor FGF -2, neuritin 1 Nrn 1 in bipolar 1 manic episode patients n = 45 and healthy control group. Results: When controlled for age, BMI and cortisol, it was found that the serum levels of BDNF, NGF, NT-3, VEGF and FGF-2 of bipolar manic episode patients were not statistically different compared to those of the control group. GDNF level and Nrn 1 levels were significantly lower P = 0.003 and P = 0.025 respectively while IGF-1 levels were significantly higher than the control group P = 0.0001 . ROC analysis was performed and the area under the the curve was calculated as 0.737, 0.766 for GDNF, IGF-1 respectively. Conclusion: The changes in the levels of GDNF, IGF-1 and Nrn 1 might be involved in pathopysiology of bipolar disorder, and GDNF, IGF-1 may be considered as state markers in bipolar manic episode.

___

  • 1. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F et al. Pathways underlying neuroprogression in bipolardisorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & Biobehavioral Reviews 2011; 35 (3): 804-817. doi: 10.1016/j.neubiorev.2010.10.001
  • 2. Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008; 33 (1): 110-133. doi: 10.1038/sj.npp.1301575
  • 3. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annual Review of Neuroscience 2001; 24: 677-736. doi: 10.1146/annurev.neuro.24.1.677
  • 4. Nikulina EM, Johnston CE, Wang J, Hammer RP. Neurotrophins in the ventral tegmental area: role in social stress, mood disorders and drug abuse. Neuroscience 2014; 27: 122-138. doi: 10.1016/j. neuroscience.2014.05.028
  • 5. Fernandes BS, Gama CS, Walz JC, Ceresér KM, Fries GR et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. Journal of Psychiatric Research 2010; 44 (9): 561-565. doi: 10.1016/j. jpsychires.2009.11.020
  • 6. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiology of Disease 2010; 37 (3): 596-603. doi: 10.1016/j.nbd.2009.11.010
  • 7. Barbosa IG, Huguet RB, Neves FS, Reis HJ, Bauer ME et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World Journal of Biological Psychiatry 2011; 12 (3): 228-232. doi: 10.3109/15622975.2010.518629
  • 8. Pochon NA, Menoud A, Tseng JL, Zurn AD, Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization.European Journal of Neuroscience1997; 9 (3): 463-471. doi: 10.1111/j.1460- 9568.1997.tb01623.x
  • 9. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cellline-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260 (5111): 1130-1132. doi: 10.1126/science.8493557
  • 10. Airaksinen M, Saarma M. The GDNF family: signaling, biological functions and therapeutic value. Nature Reviews Neuroscience 2002; 3 (5): 383-394. doi: 10.1038/nrn812
  • 11. Cheng H, Fu YS, Guo JW. Ability of GDNF to diminish free radical production leads to protection against kainite-induced excitotoxicity in hippocampus. Hippocampus 2004; 14 (1): 77-86. doi: 10.1002/hipo.10145
  • 12. Scola G, Andreazza AC. The role of neurotrophins in bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2015; 56: 122-128. doi: 10.1016/j.pnpbp.2014.08.013
  • 13. Liu X, Zhang T, He S, Hong B, Chen Z et al. Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Research 2014; 218 (1-2): 54-60. doi: 10.1016/j.psychres.2014.03.042
  • 14. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. Journal of Comparative Neurology 2000; 425 (4): 479-494. doi: 10.1002/1096-9861
  • 15. Blumberg HP, Wang F, Chepenik LG, Kalmar JH, Edmiston E et al. Influence of vascular endothelial growth factor variation on human hippocampus morphology. Biological Psychiatry 2008; 64 (10): 901-903. doi: 10.1016/j.biopsych.2008.07.003
  • 16. Lee BH, Kim YK. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. Journal of Affective Disorders 2012; 136 (1-2): 181-184. doi: 10.1016/j.jad.2011.07.021
  • 17. Trejo JL, Piriz J, Llorens-Martin MV, Fernandez AM, Bolos M et al. Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Molecular Psychiatry 2007; 12 (12): 11181128. doi: 10.1038/sj.mp.4002076
  • 18. Bezchlibnyk YB, Xu L, Wang JF, Young LT. Decreased expressionof insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Research 2007; 1147: 213-217.
  • 19. Kim YK, Na KS, Hwang JA, Yoon HK, Lee HJ et al. High insulinlike growth factor-1 in patients with bipolar I disorder: a trait marker? Journal of Affective Disorders 2013; 151 (2): 738-743. doi: 10.1016/j.jad.2013.07.041
  • 20. Abe H, Saito H. Effects of basic fibroblast growth factor on central nervous system functions. Pharmacological Research 2001; 43 (49): 307-312. doi: 10.1006/phrs.2000.0794
  • 21. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Research Bulletin 2006; 70 (3): 221-227. doi: 10.1016/j. brainresbull.2006.04.008
  • 22. Naeve GS, Ramakrishnan M, Kramer R, Hevroni D, Citri Y et al. Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis. Proceedings of the National Academy of Sciences USA 1997; 94 (6): 2648-2653. doi: 10.1073/ pnas.94.6.2648
  • 23. Putz U, Harwell C, Nedivi E. Soluble CPG15 expressed during early development rescues cortical progenitors from Apoptosis. Nature Neuroscience 2005; 8 (3): 322-331. doi: 10.1038/nn1407
  • 24. Zito A, Cartelli D, Cappelletti G, Cariboni A, Andrews W et al. Neuritin 1 promotes neuronal migration. Brain Structure & Function 2014; 219 (1): 105-118. doi: 10.1007/s00429-012-0487-1
  • 25. Son H, Banasr M, Choi M, Chae SY, Licznerski P et al. Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress. Proceedings of the National Academy of Sciences USA 2012; 109 (28): 11378-11383.doi: 10.1073/pnas.1201191109
  • 26. Chandler D, Dragović M, Cooper M, Badcock JC, Mullin BH et al. Impact of Neuritin 1 (NRN 1) polymorphism on fluid intellingence in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2010; 153B (2): 428- 437. doi: 10.1002/ajmg.b.30996
  • 27. Steen NE, Methlie P, Lorentzen S, Dieset I, Aas M et al. Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders. Journal of Psychiatric Research 2014; 52: 57-62. doi: 10.1016/j.jpsychires.2014.01.017
  • 28. Girshkin L, Matheson SL, Shepherd AM, Green MJ. Morning cortisol levels in schizophrenia and bipolar disorder: a metaanalysis. Psychoneuroendocrinology 2014; 49: 187-206. doi: 10.1016/j.psyneuen.2014.07.013
  • 29. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biological Psychiatry 2006; 59 (12): 1116-1127. doi: 10.1016/j.biopsych.2006.02.013
  • 30. Xu B, Xie X. Neurotrophic factor control of satiety and body weight. Nature Reviews Neuroscience 2016;17 (5): 282-92. doi: 10.1038/nrn.2016.24
  • 31. Roth CL, Elfers C, Gebhardt U, Müller HL, Reinehr T. Brainderived neurotrophic factor and its relation to leptin in obese children before and after weight loss. Metabolism 2013; 62 (2): 226-234. doi: 10.1016/j.metabol.2012.08.001
  • 32. Mattson MP, Arumugam TV. Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metabolism 2018; 27 (6): 1176-1199. doi: 10.1016/j. cmet.2018.05.011
  • 33. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978; 133: 429-435. doi: 10.1192/bjp.133.5.429
  • 34. First MB, Robert L, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders (SCID-I). Washington, DC, USA: American Psychiatric Press; 1997.
  • 35. Spitzer RL, Williams JBW, Gibbon M, First, M. Manual for the structured clinical interview for DSM-III-R personality disorders. Washington, DC, USA: American Psychiatric Press; 1990.
  • 36. Bora E, Fornito A, Yucel M, Pantelis C. Voxelwise metaanalysis of graymatter abnormalities in bipolar disorder. Biological Psychiatry 2010; 67 (11): 1097-1105. doi: 10.1016/j. biopsych.2010.01.020
  • 37. Tajiri M, Suzuki Y, Tsuneyama N, Arinami H, Someya T. Hormonal dynamics effect of serum insulin-like growth factor I and cortisol/dehydroepiandrosterone sulfate ratio on symptom severity of major depressive disorder. Journal of Clinical Psychopharmacology 2019; 39 (4): 367-371. doi: 10.1097/JCP.0000000000001071
  • 38. Ye F, Zhan Q, Xiao W, Sha W, Zhang X. Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia. International Journal of Methods in Psychiatric Research 2018; 27(4): e1727. doi: 10.1002/mpr.1727
  • 39. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199-211. doi: 10.1016/j.psyneuen.2014.05.011.
  • 40. Södersten K, Pålsson E, Ishima T, Funa K, Landén M et al. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. Journal of Affective Disorders 2014; 160: 1-9. doi: 10.1016/j.jad.2014.01.009
  • 41. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. Journal of Psychiatric Research 2011; 45 (8): 995-1004. doi: 10.1016/j.jpsychires.2011.03.002
  • 42. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychological Medicine 2014; 44 (11): 2409-2418. doi: 10.1017/S0033291714000014
  • 43. Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology 2009; 12 (4): 447-458. doi: 10.1017/S1461145708009310
  • 44. Ray MT, Shannon WC, Webster MJ. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Translational Psychiatry 2014; 4: e389. doi: 10.1038/tp.2014.26
  • 45. Tunca Z, Özerdem A, Ceylan D, Yalçın Y, Can G et al. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. Journal of Affective Disorders 2014; 166: 193-200. doi: 10.1016/j. jad.2014.05.012
  • 46. Li Z, Zhang C, Fan J, Yuan C, Huang J et al. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. British Journal of Psychiatry 2014; 205 (1): 29-35. doi: 10.1192/bjp.bp.113.134064
  • 47. Loch AA, Zanetti MV, de Sousa RT, Chaim TM, Serpa MH et al. Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2015; 56: 243-246. doi: 10.1016/j.pnpbp.2014.09.014
  • 48. Pan W, Banks WA, Kastin AJ. Permeability of the blood–brain barrier to neurotrophins. Brain Research 1998; 788 (1-2): 87- 94. doi: 10.1016/s0006-8993(97)01525-4
  • 49. Takebayashi M, Hisaoka K, Nishida A, Tsuchioka M, Miyoshi I et al. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. International Journal of Neuropsychopharmacology 2006; 9 (5): 607-612. doi: 10.1017/S1461145705006085
  • 50. Zhang X, ShaZW, Xie C, Xi G, Zhou H et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in bipolar patients. Journal of Affective Disorders 2010; 126 (1-2): 326- 329. doi: 10.1016/j.jad.2010.03.003
  • 51. Barbosa IG, Huguet RB, Sousa LP, Abreu MNS, Rocha NP et al. Circulating levels of GDNF in bipolar disorder. Neuroscience Letters 2011a; 502 (2): 103-106. doi: 10.1016/j. neulet.2011.07.031
  • 52. Shibata T, Yamagata H, Uchida S, Otsuki K, Hobara Tet al. The alteration of hypoxia inducible factor-1 (HIF-1) and its target genes in mood disorder patients. Progress in NeuroPsychopharmacology & Biological Psychiatry 2013; 43: 222- 229. doi: 10.1016/j.pnpbp.2013.01.003
  • 53. Kikuchi K, Iga J, Tayoshi S, Nakataki M, Watanabe S et al. Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder. Human Psychopharmacology 2011; 26 (4-5): 358-363. doi: 10.1002/ hup.1215
  • 54. Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M, RuizdeAzua S, Alberich S et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013; 44C: 29-33. doi: 10.1016/j.pnpbp.2013.01.008
  • 55. Pereira AC, McQuillin A, Puri V, Anjorin A, Bass N et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011; 156 (2): 177-187. doi: 10.1002/ajmg.b.31153
  • 56. Squassina A, Costa M, Congiu D, Manchia M, Angius A et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacological Research 2013; 73: 1-7. doi: 10.1016/j.phrs.2013.04.004
  • 57. Fatjó-Vilas M, Prats C, Pomarol-Clotet E, Lázaro L, Moreno C et al. Involvement of NRN1 gene in schizophrenia-spectrum and bipolar disorders and its impact on age at onset and cognitive functioning. World Journal of Biological Psychiatry 2016; 17 (2): 129-139. doi: 10.3109/15622975.2015.1093658
  • 58. Cappelletti G, Galbiati M, Ronchi C, Maggioni MG, Onesto E et al. Neuritin (cpg15) enhances the differentiating effect of NGF on neuronal PC12 cells. Journal of Neuroscience Research 2007; 85 (12): 2702-2713. doi:10.1002/jnr.21235
  • 59. Rickhag M, Teilum M, Wieloch T. Rapid and long-term induction of effector immediate early genes (BDNF, Neuritin and Arc) in peri-infarct cortex and dentate gyrus after ischemic injury in rat brain. Brain Research 2007; 1151: 203-210. doi: 10.1016/j.brainres.2007.03.005